2977-53-9 Usage
Uses
Used in Pharmaceutical Synthesis:
Ethanone, 1-(2,3-dichloro-4-hydroxyphenyl)is utilized as an intermediate in the synthesis of pharmaceuticals for its unique structural properties. The presence of chlorine atoms and a hydroxyl group on the phenol ring allows for versatile chemical reactions, making it a valuable component in the creation of new drug molecules.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, Ethanone, 1-(2,3-dichloro-4-hydroxyphenyl)- serves as a key building block for the synthesis of various organic compounds. Its reactive sites, including the ketone and hydroxyl groups, facilitate multiple types of chemical reactions, contributing to the development of new organic molecules with potential applications in different industries.
Used in Antioxidant and Anti-Inflammatory Applications:
Due to the presence of the hydroxyl group, Ethanone, 1-(2,3-dichloro-4-hydroxyphenyl)may exhibit antioxidant properties, which could be beneficial in protecting cells from oxidative damage. Additionally, its structure may contribute to anti-inflammatory effects, making it a potential candidate for use in treatments targeting inflammation-related conditions.
Used in Cytotoxic Studies:
The chlorine atoms in the compound may impart cytotoxic effects, which could be harnessed in the development of treatments for cancer or other conditions where the targeted destruction of cells is necessary. Further research is required to explore the full potential of Ethanone, 1-(2,3-dichloro-4-hydroxyphenyl)- in cytotoxic applications.
Note: The specific applications and industries where Ethanone, 1-(2,3-dichloro-4-hydroxyphenyl)is used are not explicitly mentioned in the provided materials. The uses listed above are inferred based on the compound's properties and potential. Further research and development are needed to confirm these applications and explore additional uses in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 2977-53-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,7 and 7 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2977-53:
(6*2)+(5*9)+(4*7)+(3*7)+(2*5)+(1*3)=119
119 % 10 = 9
So 2977-53-9 is a valid CAS Registry Number.
2977-53-9Relevant academic research and scientific papers
A two-aromatic substituted propylene ketone compound and its preparation method and application (by machine translation)
-
, (2019/05/28)
The present invention discloses a two-aromatic substituted propylene ketone compound and its preparation method and application, its structural formula such as formula (I) as shown: Wherein A is B is hydrogen, methyl or ethyl; C is a substituted benzene ring, pyridine and furan heterocyclic, 2 - pyridyl, 3 - pyridyl, 4 - pyridyl, 5 - 1 H - indolyl, 4 - (N, N - dimethylamino) phenyl, 4 - (N - pyrrolyl) phenyl, 4 - [1 - (N - methyl piperazinyl)] phenyl or 4 - (1 - morpholinyl) phenyl. The compounds of the invention has a novel structure, to inhibit the cells MCL active effect, high safety, the preparation cost is low and the like, can be used as a MCL very promising drug. (by machine translation)
Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents
Omar,Mahran,Ghatge,Chowdhury,Bamane,El-Araby,Abdulmalik,Safo
, p. 6353 - 6370 (2015/06/08)
Aromatic aldehydes and ethacrynic acid (ECA) exhibit antipolymerization properties that are beneficial for sickle cell disease therapy. Based on the ECA pharmacophore and its atomic interaction with hemoglobin, we designed and synthesized several compounds-designated as KAUS (imidazolylacryloyl derivatives)-that we hypothesized would bind covalently to βCys93 of hemoglobin and inhibit sickling. The compounds surprisingly showed weak allosteric and antisickling properties. X-ray studies of hemoglobin in complex with representative KAUS compounds revealed an unanticipated mode of Michael addition between the β-unsaturated carbon and the N-terminal αVal1 nitrogen at the α-cleft of hemoglobin, with no observable interaction with βCys93. Interestingly, the compounds exhibited almost no reactivity with the free amino acids, l-Val, l-His and l-Lys, but showed some reactivity with both glutathione and l-Cys. Our findings provide a molecular level explanation for the compounds biological activities and an important framework for targeted modifications that would yield novel potent antisickling agents.
